254 related articles for article (PubMed ID: 27382528)
1. Bromodomain Inhibitor Review: Bromodomain and Extra-terminal Family Protein Inhibitors as a Potential New Therapy in Central Nervous System Tumors.
Wadhwa E; Nicolaides T
Cureus; 2016 May; 8(5):e620. PubMed ID: 27382528
[TBL] [Abstract][Full Text] [Related]
2. The Bromodomain protein BRD4 controls HOTAIR, a long noncoding RNA essential for glioblastoma proliferation.
Pastori C; Kapranov P; Penas C; Peschansky V; Volmar CH; Sarkaria JN; Bregy A; Komotar R; St Laurent G; Ayad NG; Wahlestedt C
Proc Natl Acad Sci U S A; 2015 Jul; 112(27):8326-31. PubMed ID: 26111795
[TBL] [Abstract][Full Text] [Related]
3. Inhibition of bromodomain and extra-terminal (BET) proteins increases NKG2D ligand MICA expression and sensitivity to NK cell-mediated cytotoxicity in multiple myeloma cells: role of cMYC-IRF4-miR-125b interplay.
Abruzzese MP; Bilotta MT; Fionda C; Zingoni A; Soriani A; Vulpis E; Borrelli C; Zitti B; Petrucci MT; Ricciardi MR; Molfetta R; Paolini R; Santoni A; Cippitelli M
J Hematol Oncol; 2016 Dec; 9(1):134. PubMed ID: 27903272
[TBL] [Abstract][Full Text] [Related]
4. BET inhibitors in the treatment of hematologic malignancies: current insights and future prospects.
Abedin SM; Boddy CS; Munshi HG
Onco Targets Ther; 2016; 9():5943-5953. PubMed ID: 27729803
[TBL] [Abstract][Full Text] [Related]
5. The Bromodomain and Extra-Terminal Domain (BET) Family: Functional Anatomy of BET Paralogous Proteins.
Taniguchi Y
Int J Mol Sci; 2016 Nov; 17(11):. PubMed ID: 27827996
[TBL] [Abstract][Full Text] [Related]
6. Bromodomain inhibitors: what does the future hold?
Bhattacharya S; Piya S; Borthakur G
Clin Adv Hematol Oncol; 2018 Jul; 16(7):504-515. PubMed ID: 30067623
[TBL] [Abstract][Full Text] [Related]
7. Inhibition of bromodomain and extra-terminal proteins (BET) as a potential therapeutic approach in haematological malignancies: emerging preclinical and clinical evidence.
Chaidos A; Caputo V; Karadimitris A
Ther Adv Hematol; 2015 Jun; 6(3):128-41. PubMed ID: 26137204
[TBL] [Abstract][Full Text] [Related]
8. Bromodomain and Extra-Terminal Protein Inhibitors: Biologic Insights and Therapeutic Potential in Pediatric Brain Tumors.
Groves A; Clymer J; Filbin MG
Pharmaceuticals (Basel); 2022 May; 15(6):. PubMed ID: 35745584
[TBL] [Abstract][Full Text] [Related]
9. Bromodomain and Extraterminal Domain (BET) Protein Inhibition Hinders Glioblastoma Progression by Inducing Autophagy-Dependent Differentiation.
Colardo M; Gargano D; Russo M; Petraroia M; Pensabene D; D'Alessandro G; Santoro A; Limatola C; Segatto M; Di Bartolomeo S
Int J Mol Sci; 2023 Apr; 24(8):. PubMed ID: 37108181
[TBL] [Abstract][Full Text] [Related]
10. Pharmacological Targeting of BET Bromodomain Proteins in Acute Myeloid Leukemia and Malignant Lymphomas: From Molecular Characterization to Clinical Applications.
Reyes-Garau D; Ribeiro ML; Roué G
Cancers (Basel); 2019 Oct; 11(10):. PubMed ID: 31581671
[TBL] [Abstract][Full Text] [Related]
11. Bromodomain and extraterminal protein inhibitors in pediatrics: A review of the literature.
Jiménez I; Baruchel A; Doz F; Schulte J
Pediatr Blood Cancer; 2017 May; 64(5):. PubMed ID: 27900832
[TBL] [Abstract][Full Text] [Related]
12. Bromodomain and Extra-Terminal (BET) Domain Protein Inhibitors for Solid Tumor Cancers.
Nguyen MV; Loof L; Falchook GS
J Immunother Precis Oncol; 2020 Feb; 3(1):16-22. PubMed ID: 35756176
[TBL] [Abstract][Full Text] [Related]
13. Therapeutic targeting of polycomb and BET bromodomain proteins in diffuse intrinsic pontine gliomas.
Piunti A; Hashizume R; Morgan MA; Bartom ET; Horbinski CM; Marshall SA; Rendleman EJ; Ma Q; Takahashi YH; Woodfin AR; Misharin AV; Abshiru NA; Lulla RR; Saratsis AM; Kelleher NL; James CD; Shilatifard A
Nat Med; 2017 Apr; 23(4):493-500. PubMed ID: 28263307
[TBL] [Abstract][Full Text] [Related]
14. Bromodomains: Structure, function and pharmacology of inhibition.
Ferri E; Petosa C; McKenna CE
Biochem Pharmacol; 2016 Apr; 106():1-18. PubMed ID: 26707800
[TBL] [Abstract][Full Text] [Related]
15. Bromodomain and extra-terminal motif inhibitors: a review of preclinical and clinical advances in cancer therapy.
Alqahtani A; Choucair K; Ashraf M; Hammouda DM; Alloghbi A; Khan T; Senzer N; Nemunaitis J
Future Sci OA; 2019 Mar; 5(3):FSO372. PubMed ID: 30906568
[TBL] [Abstract][Full Text] [Related]
16. Targeting BET bromodomain proteins in solid tumors.
Sahai V; Redig AJ; Collier KA; Eckerdt FD; Munshi HG
Oncotarget; 2016 Aug; 7(33):53997-54009. PubMed ID: 27283767
[TBL] [Abstract][Full Text] [Related]
17. Bromodomain and Extraterminal Proteins as Novel Epigenetic Targets for Renal Diseases.
Morgado-Pascual JL; Rayego-Mateos S; Tejedor L; Suarez-Alvarez B; Ruiz-Ortega M
Front Pharmacol; 2019; 10():1315. PubMed ID: 31780938
[TBL] [Abstract][Full Text] [Related]
18. Bromodomain and extra-terminal inhibitors emerge as potential therapeutic avenues for gastrointestinal cancers.
Sun HY; Du ST; Li YY; Deng GT; Zeng FR
World J Gastrointest Oncol; 2022 Jan; 14(1):75-89. PubMed ID: 35116104
[TBL] [Abstract][Full Text] [Related]
19. Make your best BET: The emerging role of BET inhibitor treatment in malignant tumors.
Bechter O; Schöffski P
Pharmacol Ther; 2020 Apr; 208():107479. PubMed ID: 31931101
[TBL] [Abstract][Full Text] [Related]
20. Bromodomain and extraterminal domain protein bromodomain inhibitor based cancer therapeutics.
Halder TG; Soldi R; Sharma S
Curr Opin Oncol; 2021 Sep; 33(5):526-531. PubMed ID: 34280171
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
